Equities Analysts Issue Forecasts for Xencor FY2025 Earnings

Key Points

• Cantor Fitzgerald has projected Xencor's FY2025 earnings to be a loss of ($2.61) per share, improving from a consensus estimate of ($3.68) per share for the current year.
• Xencor's stock currently has a consensus rating of "Moderate Buy", with an average price target of $24.22 according to analysts.
• The company reported quarterly earnings beating expectations, with revenue increasing 82.4% year-over-year, highlighting strong demand for its biopharmaceutical products.

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Cantor Fitzgerald issued their FY2025 earnings estimates for Xencor in a research report issued to clients and investors on Wednesday, October 8th. Cantor Fitzgerald analyst P. Stavropoulos expects that the biopharmaceutical company will earn ($2.61) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Cantor Fitzgerald also issued estimates for Xencor's FY2026 earnings at ($3.55) EPS.

XNCR has been the topic of a number of other reports. Bank of America cut Xencor from a "buy" rating to a "neutral" rating and cut their target price for the company from $23.00 to $12.00 in a research note on Wednesday, September 3rd. Royal Bank Of Canada cut their target price on Xencor from $32.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, August 21st. Weiss Ratings reiterated a "sell (e+)" rating on shares of Xencor in a research note on Saturday, September 27th. Barclays assumed coverage on Xencor in a research note on Wednesday, September 17th. They issued an "underweight" rating and a $6.00 target price on the stock. Finally, Wedbush reiterated an "outperform" rating and issued a $26.00 target price on shares of Xencor in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.22.

Xencor Stock Performance

XNCR stock opened at $13.06 on Friday. The stock has a market capitalization of $931.48 million, a price-to-earnings ratio of -5.44 and a beta of 0.96. Xencor has a 1 year low of $6.92 and a 1 year high of $27.24. The stock's fifty day moving average is $9.09 and its two-hundred day moving average is $9.04.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.37. The firm had revenue of $43.61 million for the quarter, compared to analyst estimates of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. Xencor's quarterly revenue was up 82.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.07) earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of XNCR. GAMMA Investing LLC increased its holdings in shares of Xencor by 348.5% during the first quarter. GAMMA Investing LLC now owns 9,629 shares of the biopharmaceutical company's stock valued at $102,000 after purchasing an additional 7,482 shares during the period. Exchange Traded Concepts LLC grew its holdings in Xencor by 23.9% during the first quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 1,896 shares during the period. Diversified Trust Co acquired a new position in Xencor during the first quarter worth about $172,000. New York State Teachers Retirement System grew its holdings in Xencor by 2.1% during the first quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock worth $631,000 after acquiring an additional 1,200 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in Xencor by 2.5% during the first quarter. Principal Financial Group Inc. now owns 348,726 shares of the biopharmaceutical company's stock worth $3,710,000 after acquiring an additional 8,581 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.